NCT00005017 is a Phase 4 clinical trial of Ritonavir in HIV Infections, sponsored by Glaxo Wellcome.

Who is sponsoring NCT00005017?

NCT00005017 is sponsored by Glaxo Wellcome.

What drugs are being tested in NCT00005017?

Interventions in NCT00005017: Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Lamivudine, Stavudine.

What condition does NCT00005017 study?

NCT00005017 studies HIV Infections.

Is NCT00005017 still recruiting?

NCT00005017 is currently status unknown. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00005017

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive

Status unknown Phase 4 Last updated 23 June 2005

What this trial tests

Phase 4 trial testing Ritonavir in HIV Infections in 300 participants. Status unknown.

Quick facts

Lead sponsor	Glaxo Wellcome
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	300
Sites	1 location across United States

Drugs / interventions tested

Ritonavir (ritonavir) — full drug profile →
Abacavir sulfate
Amprenavir (AMPRENAVIR) — full drug profile →
Efavirenz (EFAVIRENZ) — full drug profile →
Lamivudine (LAMIVUDINE) — full drug profile →
Stavudine

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Glaxo Wellcome — full company profile →

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir (APV)/ritonavir (RTV).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ritonavir

Trials testing the same drug.

NCT06428045 — STARLITE for Unresectable High-Grade Gliomas · Phase 1 · recruiting
NCT05965726 — RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms · Phase 2 · completed
NCT05668091 — A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID. · Phase 2 · completed
NCT05679388 — A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patient · Phase 1 · terminated
NCT05545319 — A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immun · Phase 2 · withdrawn

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00005017 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Glaxo Wellcome
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00005017.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing